Blood markers to spot hidden cancer in people with venous thromboembolism
Studies blood markers of inflammation to find hidden cancer in people with blood clots.
Key facts
- Who runs it
- Danderyd Hospital
- Where
- Sweden2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Mar 2017
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Record updated
- 20 December 2018
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a new blood clot in a deep vein or in the lungs (venous thromboembolism). It studies blood markers that may help find hidden cancer.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- A blood clot in the deep veins of the arms, legs or pelvis (iliac veins), and/or in the lungs. It must be found by ultrasound, phlebography, CT scan or angiography.
Main reasons for not taking part
- More than 2 days have passed since the blood clot was diagnosed
- No blood sample taken at the start of the study
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
- > 18 years or older
- Written informed consent
Who cannot take part
- > 2 days after VTE diagnosis
- No blood withdrawal at baseline
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Venous thromboembolism is a common and serious complication in cancer, and is associated with a substantially increased morbidity and mortality. Furthermore, VTE may be the earliest sign of cancer. Recent studies, however, fail to show a clinical benefit of extended cancer screening in this patient population. Better risk prediction models are therefore warranted to identify VTE patients who would benefit from a rapid and extensive cancer screening. Inflammation and hypercoagulability are considered hallmarks of cancer, and emerging light is being shed on the potential of various markers of inflammation and coagulation in cancer diagnostics and prognostics. Among the inflammatory and thrombotic processes linked to cancer is the neutrophil release of web-like nuclear chromatin (DNA and histones), referred to as neutrophil extracellular traps (NETs). Driven by the tumor environment, NETs have recently been shown to play a central role in tumor progression, metastasis, and tumor-associated thrombosis.
Read full original descriptionShow less
The investigators hypothesize that an enhanced inflammatory state may be predictive of an underlying cancer in patients presenting with VTE. The present study is an ongoing prospective study with the primary aim to investigate the diagnostic potential of markers of inflammation, including markers of NETs, in detecting occult cancer in patients presenting with VTE. Secondary aims are to include other biomarkers of cancer, and to assess whether any or a combination of these biomarkers may be prognostic of occult cancer, recurrent thrombotic events, mortality, or cancer disease progression in VTE patients with an underlying malignancy.
The group in the trial
- Venous thromboembolism
Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism
- Plain-language title
- Blood markers to spot hidden cancer in people with venous thromboembolismGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 20 December 2018